ArticleMolecular therapy : the journal of the American Society of Gene Therapy2014

Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure.

Javier Moreno-Montañés et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.